Literature DB >> 33344183

Comparative study on pharmacokinetics and toxicity of intravitreal and sub-Tenon injection of triamcinolone acetonide in ocular tissues.

Yuko Arie1, Hiroko Miyai1, Ayako Suzuki1, Takeshi Okabe1, Mitsuyo Takashima1, Mayumi Takata1, Takashi Kurasawa1, Masaki Ito1, Reijiro Arakawa1, Yuichiro Ogura2, Akira Naito1.   

Abstract

AIM: To compare the differences in kinetics, distribution, and toxicity of triamcinolone acetonide (TA) between the injection methods, sub-Tenon and intravitreal injections in rabbit ocular tissues.
METHODS: TA was injected into the vitreous or the sub-Tenon in rabbits. For pharmacokinetic study, rabbits were sacrificed periodically and then TA in blood and ocular tissues (retina/choroids, vitreous, and aqueous humor) were measured over 91d. For toxicological study, clinical signs, slit-lamp microscopic examination, ophthalmological test were performed. The eyeballs and surrounding tissues were collected and fixed with glutaraldehyde-formalin solution, and then paraffin embedded for histological investigation.
RESULTS: Higher levels of TA were distributed in the intraocular tissues when injected into the vitreous compared to the sub-Tenon. Conversely, TA level was remarkably lower in the rabbits which received intravitreal TA injections than those treated with sub-Tenon injection throughout the study period in plasma. Optical discharge probably caused by systemic circulation of TA was observed by receiving sub-Tenon TA injection. Meanwhile, technic-associated toxicological ocular symptoms and findings were more frequently observed in intravitreal injection than in sub-Tenon injection.
CONCLUSION: There are significant differences in kinetics and distribution of TA in vitreous body, aqueous humor and plasma, between the two injection methods. Although further study is needed to explain the species difference between human and rabbit, it is assumed that the difference in the frequency of intraocular pressure elevation and cataract formation by TA between the two injection methods are directly related to the TA concentrations in aqueous humor and vitreous body in each injection methods. Systemic toxicity and technic-associated toxicity are also closely related to kinetics of TA in plasma and each injection method itself, respectively. International Journal of Ophthalmology Press.

Entities:  

Keywords:  corticosteroid(s); injection; ophthalmic drug delivery; pharmacokinetics; toxicity

Year:  2020        PMID: 33344183      PMCID: PMC7708352          DOI: 10.18240/ijo.2020.12.04

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  33 in total

1.  Evaluation of triamcinolone acetonide following intravitreal injection in New Zealand white rabbits.

Authors:  David H McGee; Olga Dembinska; Margarita M Gruebbel
Journal:  Int J Toxicol       Date:  2005 Nov-Dec       Impact factor: 2.032

2.  Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.

Authors:  Paul M Beer; Sophie J Bakri; Ravinder J Singh; Weiguo Liu; George B Peters; Michael Miller
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.

Authors:  Michael R Robinson; Susan S Lee; Hyuncheol Kim; Stephanie Kim; Robert J Lutz; Craig Galban; Peter M Bungay; Peng Yuan; Nam Sun Wang; Jonghyeon Kim; Karl G Csaky
Journal:  Exp Eye Res       Date:  2005-09-15       Impact factor: 3.467

4.  Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2008-12

Review 5.  Transport barriers in transscleral drug delivery for retinal diseases.

Authors:  Stephanie H Kim; Robert J Lutz; Nam Sun Wang; Michael R Robinson
Journal:  Ophthalmic Res       Date:  2007-09-12       Impact factor: 2.892

6.  Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema.

Authors:  Andrew A Chang; Haitao Li; Geoffrey K Broadhead; Kehui Luo; Meidong Zhu
Journal:  J Ocul Pharmacol Ther       Date:  2015-07-28       Impact factor: 2.671

7.  Effects of sub-Tenon's triamcinolone injections in patients with uveitis.

Authors:  Bianca Gubiani Ferreira; Diane Ruschel Marinho; Felipe Teloken Diligenti
Journal:  Arq Bras Oftalmol       Date:  2018 Jul-Aug       Impact factor: 0.872

8.  Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon's triamcinolone acetonide for uveitic cystoid macular oedema.

Authors:  Sreekanth Sreekantam; Trystan Macdonald; Pearse A Keane; Dawn A Sim; Philip I Murray; Alastair K Denniston
Journal:  Br J Ophthalmol       Date:  2016-05-05       Impact factor: 4.638

9.  Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries.

Authors:  Hammouda Hamdy Ghoraba; Mahmoud Leila; Sameh Mohamed Elgouhary; Emad Eldin Mohamed Elgemai; Haithem Mamon Abdelfattah; Hashem Hammouda Ghoraba; Mohamed Amin Heikal
Journal:  Clin Ophthalmol       Date:  2018-11-26

10.  Delivery of intraocular triamcinolone acetonide in the treatment of macular edema.

Authors:  Aaron Pickrell; Alon Harris; Sandra Ngo; Annahita Amireskandari; Erin Stewart; Brent Siesky
Journal:  Pharmaceutics       Date:  2012-03-15       Impact factor: 6.321

View more
  1 in total

1.  Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.

Authors:  Taiichi Hikichi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-02       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.